Stifel analyst Rick Wise raised the firm’s price target on Boston Scientific to $58 from $52 and keeps a Buy rating on the shares. Boston Scientific Q1 results outperformed across the board, the analyst tells investors. Stifel sees multiple catalysts in 2024+ and argues for long-term 6%-8% growth upside potential. Similar to CEO Mike Mahoney, the firm is "very excited about the future of the company."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific price target raised to $56 from $53 at RBC Capital
- Boston Scientific price target raised to $55 from $45 at Deutsche Bank
- Boston Scientific commentary lowers odds of ShockWave deal, says Evercore
- Boston Scientific price target raised to $58 from $53 at Canaccord
- Boston Scientific price target raised to $56 from $53 at Barclays